A 4-Day, Randomized, Controlled, Open Application Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers, Using a Phototoxicity Test Design.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Actinic keratosis; Skin cancer
- Focus Adverse reactions
- Sponsors Peplin
- 21 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Feb 2009 New trial record